Methods	Six-week randomised, double-blind study.
Participants	Patients fulfilling DSM-III criteria for major depressive disorder, with a score of at least 17 on the first 17 items of the HDRS, a score of at least 8 on the Raskin, greater than Covi. Age range: 18-65 years old. Exclusion criteria: history of manic episode, pregnancy, lactation, absence of contraception, glaucoma, chronic urinary retention, brain or other significant organic illness, schizophrenia, other mental illness or severe suicidal risk, recent history (less than 1 year) of alcohol or drug abuse, concurrent treatment with other psychotropic drug including lithium, use of MAOI less of 2 weeks prior the study entry
Interventions	Fluoxetine: 60 participants. Clomipramine: 60 participants. Fluoxetine dose range: 20-40 mg/day. Clomipramine dose: 100 mg/day. Chloralzepate (10 mg) for insomnia was allowed.
Outcomes	Hamilton Rating Scale for Depression (HDRS-21), Raskin Depression Scale, Covi Anxiety Scale, PGI, CGI
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear